Amalgamated Bank Has $248,000 Stock Position in AdaptHealth Corp. (NASDAQ:AHCO)

Amalgamated Bank trimmed its holdings in shares of AdaptHealth Corp. (NASDAQ:AHCO) by 8.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,003 shares of the company’s stock after selling 3,145 shares during the period. Amalgamated Bank’s holdings in AdaptHealth were worth $248,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Deerfield Management Company L.P. Series C raised its position in AdaptHealth by 22.7% during the third quarter. Deerfield Management Company L.P. Series C now owns 13,607,940 shares of the company’s stock valued at $123,832,000 after buying an additional 2,513,026 shares during the period. Vanguard Group Inc. grew its stake in AdaptHealth by 4.3% in the third quarter. Vanguard Group Inc. now owns 8,656,553 shares of the company’s stock valued at $78,775,000 after purchasing an additional 355,005 shares in the last quarter. Reinhart Partners LLC. grew its stake in AdaptHealth by 12.2% in the fourth quarter. Reinhart Partners LLC. now owns 4,065,695 shares of the company’s stock valued at $29,639,000 after purchasing an additional 443,518 shares in the last quarter. Kennedy Capital Management LLC grew its stake in AdaptHealth by 149.3% in the third quarter. Kennedy Capital Management LLC now owns 1,483,640 shares of the company’s stock valued at $13,501,000 after purchasing an additional 888,504 shares in the last quarter. Finally, LGT Capital Partners LTD. grew its stake in AdaptHealth by 79.4% in the fourth quarter. LGT Capital Partners LTD. now owns 1,000,000 shares of the company’s stock valued at $7,290,000 after purchasing an additional 442,500 shares in the last quarter. 82.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at AdaptHealth

In related news, major shareholder James E. Flynn sold 182,607 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the completion of the sale, the insider now owns 11,643,769 shares in the company, valued at approximately $128,314,334.38. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, major shareholder James E. Flynn sold 52,487 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $10.93, for a total transaction of $573,682.91. Following the completion of the sale, the insider now owns 11,826,376 shares in the company, valued at approximately $129,262,289.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder James E. Flynn sold 182,607 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the sale, the insider now owns 11,643,769 shares of the company’s stock, valued at approximately $128,314,334.38. The disclosure for this sale can be found here. 4.43% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AHCO. UBS Group boosted their target price on AdaptHealth from $9.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Truist Financial restated a “buy” rating and issued a $13.00 target price on shares of AdaptHealth in a research note on Wednesday, May 15th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $13.00 target price on shares of AdaptHealth in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $12.42.

AdaptHealth Stock Performance

AHCO opened at $9.72 on Thursday. The company has a market cap of $1.29 billion, a PE ratio of -1.84, a price-to-earnings-growth ratio of 0.76 and a beta of 1.06. The stock has a 50-day moving average of $10.19 and a 200-day moving average of $8.74. AdaptHealth Corp. has a 52-week low of $6.37 and a 52-week high of $15.37. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.11 and a current ratio of 1.33.

AdaptHealth (NASDAQ:AHCO) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.44. The company had revenue of $858.23 million during the quarter, compared to the consensus estimate of $825.94 million. AdaptHealth had a positive return on equity of 8.47% and a negative net margin of 21.45%. As a group, equities research analysts forecast that AdaptHealth Corp. will post 0.8 earnings per share for the current fiscal year.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.